Skip to main content
. Author manuscript; available in PMC: 2021 Apr 27.
Published in final edited form as: Cancer Biomark. 2020;27(3):407–421. doi: 10.3233/CBM-190988

Fig. 4.

Fig. 4.

A–D. Individual antigen plots for 4 antigens, TRIM21, NY-ESO-1, TP53, and PAX8 in Validation II. E. Maximum value of TRIM21, NY-ESO-1, TP53, or PAX8 in Validation II. The immunoreactivity as defined by the ratio of 800/700 is standardized for each antigen to provide the threshold of Mean + 2 (StdDev) for healthy controls, as indicated by the horizontal line at Y = 2.